May 14 session to focus on chemically modified CRISPR guides for multi‑organ delivery
- Keystone Symposia’s March 10 program in Banff listed a talk by UC Berkeley’s Wayne Ngo on “chemically modified CRISPR enzymes” for multi-organ editing in vivo. - The same meeting paired that delivery session with Anastasia Khvorova on iPhos lipid nanoparticles, underscoring that organ targeting now sits beside editing itself. - That shift matters because CRISPR’s bottleneck is moving from cut accuracy to getting editors safely into the right tissues.
CRISPR editing is getting good enough that the hard part is no longer just the cut. The hard part is delivery — getting the editor and its guide RNA into the right cells, in the right organs, at a useful dose, without setting off toxicity or immune alarms. That is why a session on chemically modified CRISPR components matters. The real news is not just that one talk exists. It is that major 2026 genome-engineering programs are now treating delivery chemistry as a front-line scientific problem, not a side issue. ### What was actually scheduled? A Keystone Symposia meeting called *Precision Genome Engineering: From Basic Mechanisms to Application* listed a March 10, 2026 spotlight session on screening and delivery, including Wayne Ngo of UC Berkeley speaking on “Chemically Modified CRISPR Enzymes for Multi-organ Genome Editing in vivo.” The same program also included delivery-focused talks from Daniel Siegwart and Anastasia Khvorova, which tells you this was not a one-off curiosity — it sat inside a broader delivery track. (keystonesymposia.org) ### Why do chemical modifications matter so much? Guide RNAs are fragile. In the body, nucleases chew them up fast, innate immune sensors can react to them, and many formulations struggle to move beyond one favored tissue. Chemical modifications are basically a way to toughen the guide up — changing parts of the RNA so it lasts longer, travels better, and stays functional once it reaches cells. That playbook already works in oligonucleotide drugs, so CRISPR researchers are borrowing it hard. (keystonesymposia.org) ### Why is multi-organ editing the hard version? Editing one organ is already difficult. The liver is the classic first target because many nanoparticles naturally end up there after intravenous dosing. But diseases do not always cooperate. Some need editing in muscle, lung, brain, or several tissues at once. Multi-organ delivery means solving a routing problem and a stability problem at the same time — more like sending a package through several customs checkpoints than dropping it at one familiar address. (pmc.ncbi.nlm.nih.gov) ### So are modified guides enough on their own? Usually not. The guide chemistry and the carrier chemistry have to work together. That is why it matters that the same Keystone program also featured Khvorova on ionizable phospholipid, or iPhos, lipid nanoparticles that control where payloads go. The field is converging on a combo approach: redesign the RNA, redesign the particle, and sometimes redesign the editor protein too. (sciencedirect.com) ### Has anyone shown this can work? Yes — at least preclinically. A 2024 *Nucleic Acids Research* paper described heavily modified CRISPR RNAs that improved stability and supported in vivo genome editing, including “self-delivering” designs meant to reduce dependence on standard lipid nanoparticle packaging. That does not mean the delivery problem is solved. But it does show that guide chemistry can move from a cleanup tweak to a core performance lever. (keystonesymposia.org) ### Why is this becoming more urgent now? Because the editing side keeps advancing. Clinical CRISPR programs are growing, and as more therapies move toward real patients, the old lab answer — “we can edit this in cells” — stops being enough. You need something manufacturable, repeatable, and tissue-relevant. In 2026, that pushes delivery from a technical detail into the main event. (academic.oup.com) ### What is the catch? Every modification is a tradeoff. Change the guide too much and the editor may stop recognizing it well. Change the particle too aggressively and biodistribution may improve while toxicity worsens. The field is chasing a narrow corridor where stability, potency, specificity, manufacturability, and safety all hold at once. That is why these talks matter even before they produce a drug. They show where the bottleneck really is. (innovativegenomics.org) ### Bottom line? The important shift is conceptual. CRISPR used to be framed mostly as a targeting-and-cutting technology. Now the frontier is chemical engineering around the editor — especially the guide RNA and the delivery vehicle. If researchers can make those pieces robust enough for more than one organ, the range of diseases CRISPR can realistically treat gets much bigger. (keystonesymposia.org) (academic.oup.com)
